Neuren Pharmaceuticals Limited has released a press release.
Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
Earlier from Neuren Pharmaceuticals
- DAYBU recommended for approval in the European Union
- Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
- DAYBUE STIX now broadly available in US for Rett syndrome
- Acadia confirms plan to request CHMP re-examination